Overview Solifenacin Succinate Versus Tolterodine 4mg Once Daily Status: Completed Trial end date: 2004-10-01 Target enrollment: Participant gender: Summary Prospective, double-blind, double-dummy, 2-arm, parallel-group, design. Flexible dose regimen for solifenacin succinate, fixed dose treatment regimen for tolterodine. Assessment of OAB symptoms by patient diaries. Phase: Phase 3 Details Lead Sponsor: Astellas Pharma IncTreatments: Solifenacin SuccinateTolterodine Tartrate